Innovating to improve health worldwide

Artificial intelligence in pharmaceutical manufacturing – navigating innovation and regulation

Artificial Intelligence (AI) and Machine Learning (ML) are rapidly transforming various sectors, and the pharmaceutical manufacturing industry is no exception. This paper explores how the pharmaceutical industry may use individual applications of AI in pharmaceutical manufacturing and control. It describes the evolving regulatory landscape and provides key considerations for national regulatory authorities (NRA) when reviewing...

Financing health systems: Leveraging the benefits of investing in prevention against NCDs

Investing in the prevention and treatment of non-communicable diseases (NCDs) can strengthen health systems, protect economic productivity, and improve population wellbeing. Evidence shows that every dollar invested in preventing and managing NCDs generates substantial returns through reduced healthcare costs, improved workforce participation, and healthier, more resilient societies. Yet despite this compelling investment case, progress remains...

Why orphan medicines remain out of reach in low- and middle-income countries – and what can be done

Rare diseases, comprised of more than 7,000 conditions, are a major global health challenge, affecting over 300 million people worldwide. In low- and middle-income countries (LMICs), the burden is substantial and likely underestimated due to underdiagnosis, weak surveillance, and limited access to early diagnosis and preventive care. Even where treatments exist, access to orphan medicines...